![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 10
2025
Tomsitz, Dirk 
ORCID: https://orcid.org/0000-0003-0036-072X; Livingstone, Elisabeth; Loquai, Carmen; Kaatz, Martin; Leiter, Ulrike ORCID: https://orcid.org/0000-0002-8019-1577; Schilling, Bastian ORCID: https://orcid.org/0000-0001-8859-4103; Terheyden, Patrick; Hassel, Jessica; Sachse, Michael; Ulrich, Jens; Dippel, Edgar; Meiss, Frank; Pföhler, Claudia; Kreuter, Alexander; Herbst, Rudolf; Weichenthal, Michael; Zimmer, Lisa; Meier, Friedegund; Rauschenberg, Ricarda; Mohr, Peter; Brunnert, Fiona; von Wasielewski, Imke; Gutzmer, Ralf; Schadendorf, Dirk ORCID: https://orcid.org/0000-0003-3524-7858; Berking, Carola ORCID: https://orcid.org/0000-0003-0229-8931; Ugurel, Selma und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(22. März 2025):
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.
In: Journal of the European Academy of Dermatology and Venereology, Bd. 39, Nr. 11: S. 1975-1986
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-0036-072X; Livingstone, Elisabeth; Loquai, Carmen; Kaatz, Martin; Leiter, Ulrike ORCID: https://orcid.org/0000-0002-8019-1577; Schilling, Bastian ORCID: https://orcid.org/0000-0001-8859-4103; Terheyden, Patrick; Hassel, Jessica; Sachse, Michael; Ulrich, Jens; Dippel, Edgar; Meiss, Frank; Pföhler, Claudia; Kreuter, Alexander; Herbst, Rudolf; Weichenthal, Michael; Zimmer, Lisa; Meier, Friedegund; Rauschenberg, Ricarda; Mohr, Peter; Brunnert, Fiona; von Wasielewski, Imke; Gutzmer, Ralf; Schadendorf, Dirk ORCID: https://orcid.org/0000-0003-3524-7858; Berking, Carola ORCID: https://orcid.org/0000-0003-0229-8931; Ugurel, Selma und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(22. März 2025):
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.
In: Journal of the European Academy of Dermatology and Venereology, Bd. 39, Nr. 11: S. 1975-1986
[PDF, 1MB]
Tomsitz, Dirk; Grabmaier, Ulrich; Spiro, Judith; Nicolai, Leo ORCID: https://orcid.org/0000-0003-0776-5885; French, Lars E. ORCID: https://orcid.org/0000-0002-4629-1486; Massberg, Steffen ORCID: https://orcid.org/0000-0001-7387-3986 und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(5. Februar 2025):
Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T.
In: European Journal of Cancer, Bd. 216, 115186
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-0776-5885; French, Lars E. ORCID: https://orcid.org/0000-0002-4629-1486; Massberg, Steffen ORCID: https://orcid.org/0000-0001-7387-3986 und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(5. Februar 2025):
Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T.
In: European Journal of Cancer, Bd. 216, 115186
[PDF, 1MB]
Tomsitz, Dirk; Zimmermann, Petra; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952; Neumann, Jens; Siegmund, Birte J.; Weiss, Bernhard G. ORCID: https://orcid.org/0000-0002-8368-0149; Kauke, Teresa ORCID: https://orcid.org/0000-0001-6569-9703; Sienel, Wulf; French, Lars E. ORCID: https://orcid.org/0000-0002-4629-1486; Klauschen, Frederick ORCID: https://orcid.org/0000-0002-9131-2389 und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(2025):
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study.
In: JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Bd. 23, Nr. 5: S. 600-608
ORCID: https://orcid.org/0000-0002-5021-1952; Neumann, Jens; Siegmund, Birte J.; Weiss, Bernhard G. ORCID: https://orcid.org/0000-0002-8368-0149; Kauke, Teresa ORCID: https://orcid.org/0000-0001-6569-9703; Sienel, Wulf; French, Lars E. ORCID: https://orcid.org/0000-0002-4629-1486; Klauschen, Frederick ORCID: https://orcid.org/0000-0002-9131-2389 und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(2025):
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study.
In: JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Bd. 23, Nr. 5: S. 600-608
DeTemple, Viola K. ORCID: https://orcid.org/0000-0001-6246-8862; Kaatz, Martin ORCID: https://orcid.org/0000-0002-0650-2576; Stockfleth, Eggert; Scheel, Christina; Angela, Yenny ORCID: https://orcid.org/0000-0002-6643-7286; Gutzmer, Ralf ORCID: https://orcid.org/0000-0001-7921-2820; Leiter, Ulrike; Meier, Friedegund ORCID: https://orcid.org/0000-0003-4340-9706; Schadendorf, Dirk ORCID: https://orcid.org/0000-0003-3524-7858; Livingstone, Elisabeth ORCID: https://orcid.org/0000-0001-8279-9239; Gebhardt, Christoffer ORCID: https://orcid.org/0000-0001-7090-9584; Wasielewski, Imke von; Weichenthal, Michael ORCID: https://orcid.org/0000-0002-9060-4961; Mohr, Peter; Hassel, Jessica ORCID: https://orcid.org/0000-0001-7575-6230; Pföhler, Claudia ORCID: https://orcid.org/0000-0003-0384-114X; Simon, Jan Christoph; Jochims, Franziska ORCID: https://orcid.org/0000-0003-2279-2072; Terheyden, Patrick; Ulrich, Jens; Haferkamp, Sebastian; Drexler, Konstantin; Schilling, Bastian; Glutsch, Valerie ORCID: https://orcid.org/0000-0001-9291-1327; Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643; Berking, Carola; Ugurel, Selma ORCID: https://orcid.org/0000-0002-9384-6704 und Tomsitz, Dirk ORCID: https://orcid.org/0000-0003-0036-072X
(2025):
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
In: European Journal of Cancer, Bd. 225, 115590
[PDF, 2MB]
ORCID: https://orcid.org/0000-0001-6246-8862; Kaatz, Martin ORCID: https://orcid.org/0000-0002-0650-2576; Stockfleth, Eggert; Scheel, Christina; Angela, Yenny ORCID: https://orcid.org/0000-0002-6643-7286; Gutzmer, Ralf ORCID: https://orcid.org/0000-0001-7921-2820; Leiter, Ulrike; Meier, Friedegund ORCID: https://orcid.org/0000-0003-4340-9706; Schadendorf, Dirk ORCID: https://orcid.org/0000-0003-3524-7858; Livingstone, Elisabeth ORCID: https://orcid.org/0000-0001-8279-9239; Gebhardt, Christoffer ORCID: https://orcid.org/0000-0001-7090-9584; Wasielewski, Imke von; Weichenthal, Michael ORCID: https://orcid.org/0000-0002-9060-4961; Mohr, Peter; Hassel, Jessica ORCID: https://orcid.org/0000-0001-7575-6230; Pföhler, Claudia ORCID: https://orcid.org/0000-0003-0384-114X; Simon, Jan Christoph; Jochims, Franziska ORCID: https://orcid.org/0000-0003-2279-2072; Terheyden, Patrick; Ulrich, Jens; Haferkamp, Sebastian; Drexler, Konstantin; Schilling, Bastian; Glutsch, Valerie ORCID: https://orcid.org/0000-0001-9291-1327; Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643; Berking, Carola; Ugurel, Selma ORCID: https://orcid.org/0000-0002-9384-6704 und Tomsitz, Dirk ORCID: https://orcid.org/0000-0003-0036-072X
(2025):
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
In: European Journal of Cancer, Bd. 225, 115590
[PDF, 2MB]
2024
Tomsitz, Dirk; Kerl, Katrin; French, Lars Einar ORCID: https://orcid.org/0000-0002-4629-1486 und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(2024):
Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients.
In: Journal of the American Academy of Dermatology, Bd. 91, Nr. 6: S. 1136-1142
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-4629-1486 und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(2024):
Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients.
In: Journal of the American Academy of Dermatology, Bd. 91, Nr. 6: S. 1136-1142
[PDF, 1MB]
2022
Zierold, Sarah; Akcetin, Larissa Semra; Gresser, Eva; Maier, Anna Marie; König, Alexander; Kramer, Rafaela; Theurich, Sebastian; Tomsitz, Dirk; Erdmann, Michael; French, Lars E.; Rudelius, Martina und Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643
(2022):
Checkpoint-inhibitor induced Polyserositis with Edema.
In: Cancer Immunology Immunotherapy, Bd. 71, Nr. 12: S. 3087-3092
[PDF, 658kB]
ORCID: https://orcid.org/0000-0001-5718-3643
(2022):
Checkpoint-inhibitor induced Polyserositis with Edema.
In: Cancer Immunology Immunotherapy, Bd. 71, Nr. 12: S. 3087-3092
[PDF, 658kB]
Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael M.; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kahler, Katharina C.; French, Lars E. und Heinzerling, Lucie
(2022):
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases.
In: Data in Brief, Bd. 45, 108676
[PDF, 312kB]
Tomsitz, Dirk; Schlaak, Max; Zierold, Sarah; Pesch, Giulia; Schulz, Thomas U.; Müller, Genoveva; Zecha, Christine; French, Lars E. und Heinzerling, Lucie
(2022):
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma.
In: Cancers, Bd. 14, Nr. 13
[PDF, 634kB]
Cartun, Zachary; Kunz, Wolfgang G.; Heinzerling, Lucie; Tomsitz, Dirk; Guertler, Anne; Westphalen, C. Benedikt; Ricke, Jens; Weir, William; Unterrainer, Marcus und Mehrens, Dirk
(2022):
Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
In: JAMA Dermatology, Bd. 158, Nr. 12: S. 1387-1393
Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael M.; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kaehler, Katharina C.; French, Lars E. und Heinzerling, Lucie
(2022):
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
In: European Journal of Cancer, Bd. 176: S. 88-99